Cancer diagnosis and mortality in patients with ankylosing spondylitis: A Western Australian retrospective cohort study

Abstract Background The purpose of this study was to determine the prevalence of high disease activity as measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS) in ankylosing spondylitis (AS) patients who nonetheless have low Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores after anti-tumor necrosis factor (TNF) treatment. Its clinical impact on anti-TNF survival was also investigated. Methods We conducted a single-centre retrospective cohort study of AS patients having low BASDAI scores (< 4) and available ASDAS-C-reactive protein (CRP) data after 3 months of first-line anti-TNF treatment. Patients were grouped into high-ASDAS (≥ 2.1) and low-ASDAS (< 2.1) groups according to the ASDAS-CRP after 3 months of anti-TNF treatment. Their characteristics were compared. And survival analyses were carried out using Kaplan–Meier curves and log-rank test with the event being discontinuation of anti-TNF treatment due to lack/loss of efficacy. Results Among 116 AS patients with low BASDAI scores after 3 months of anti-TNF treatment, 38.8% were grouped into the high-ASDAS group. The high-ASDAS group tended to have greater disease activity after 9 months of treatment (BASDAI 2.9 ± 1.1 vs. 2.3 ± 1.4, p=0.007; ASDAS-CRP 1.8 ± 0.6 vs. 1.5 ± 0.7, p=0.079; proportion of high ASDAS-CRP 27.8% vs. 13.8%, p=0.094) and greater risk of discontinuing anti-TNF treatment due to lack/loss of efficacy than the low-ASDAS group (p=0.011). Conclusions A relatively high proportion of AS patients with low BASDAI scores had high ASDAS-CRP. These low-BASDAI/high-ASDAS-CRP patients also had a greater risk for discontinuation of anti-TNF treatment due to low/lack of efficacy than the low-ASDAS group. The use of the ASDAS-CRP alone or in addition to the BASDAI may improve the assessment of AS patients treated with anti-TNF agents.

Download Full-text

THU0211 Low Dose Etanercept Treatment for Maintenance of Clinical Remission in Ankylosing Spondylitis: Retrospective Cohort Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2264 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 272.2-273

Author(s):

J.W. Park ◽

Y.I. Yoon ◽

S.H. Chang ◽

E.B. Lee ◽

Y.W. Song ◽

...

Keyword(s):

Cohort Study ◽

Ankylosing Spondylitis ◽

Retrospective Cohort Study ◽

Clinical Remission ◽

Retrospective Cohort ◽

Low Dose ◽

Etanercept Treatment

Download Full-text

Knowing Cancer Diagnosis is a Protective Factor for the Survival of Patients With Breast Cancer : A Retrospective Cohort Study

10.21203/rs.3.rs-105383/v1 ◽

2020 ◽

Author(s):

Chen He ◽

Wenxi Zhu ◽

Yunxiang Tang ◽

Yonghai Bai ◽

Zheng Luo ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Survival Time ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Breast Cancer Patients ◽

Term Survival ◽

Cox Regression Analysis

Abstract Background: The health burden of breast cancer is rising in China. The effect of informed diagnosis on long-term survival has not been fully understood. This retrospective cohort study aims at exploring the association between early informed diagnosis and survival time in breast cancer patients.Methods: 12,327 breast cancer patients were enrolled between October 2002 and December 2016. Potential factors including knowing cancer diagnosis status, gender, age, clinical-stage, surgical history, the grade of reporting hospital and diagnostic year were registered. We followed up all participants every 6 months until June 2017.Results: By June 2017, 18.04% of the participants died of breast cancer. Both the 3-year and 5-year survival rate of whom knew cancer diagnosis were longer (P<0.001). By stratified analysis, except subgroups of male patients and patients in stage III, patients knowing diagnosis showed a better prognosis in all the other subgroups (P<0.05). By Cox regression analysis, it was showed that not knowing cancer diagnosis was an independent risk factor for survival in breast cancer patients (P<0.001).Conclusions: Being aware of their cancer diagnosis plays a protective role in extending the survival time in breast cancer patients, which suggests medical staff and patients’ families disclose cancer diagnosis to patients timely.

Download Full-text